| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
Vir Biotechnology, Inc. (the Company) is holding a virtual investor conference call at 5:30 a.m. PT / 8:30 a.m. ET on November 9, 2026, to discuss the topline results from the pivotal Phase 3 ECLIPSE 1 clinical trial evaluating monthly s... |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Topline data from pivotal Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 |
| 28 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board fr... |
| 14 Oct 2026 |
8-K: Unregistered Sales of Equity Securities; Other Events
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors |
| 08 Oct 2026 |
8-K: Other Events
Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer |
| 01 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN FRANCISCO, Calif. October 1, 2026 – Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr. Sa... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
– Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment |
| 24 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 20, 2026, Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another op... |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 9, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from s... |
| 28 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
– Global strategic collaboration with Astellas to advance PSMA-targeted, PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 closed and first patient dosed in Phase 1 dose-expansion cohorts in patients with late-line metastatic prostate ... |
| 10 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026. The Company ... |
| 04 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 02 Mar 2026 |
8-K: Other Events
As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on February 26, 2026, Vir Biotechnology, Inc. (Vir Bio) entered into an underwriting agreement (the Underwriting Agreement) with Go... |
| 26 Feb 2026 |
8-K: Entry into a Material Definitive Agreement
As representatives (the “Representatives”) of the several Underwriters |
| 23 Feb 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
– Announces global strategic collaboration with Astellas to advance PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE) VIR-5500 for the treatment of prostate cancer |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
January 14, 2026 J.P. Morgan 2026 Healthcare Conference 2026 Vir Biotechnology, Inc. 1 |
| 16 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
– ECLIPSE 1 enrollment completed approximately two months ahead of schedule; ECLIPSE 2 and ECLIPSE 3 progressing with strong enrollment momentum, with topline data for all three studies expected in the first quarter of 2027 |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
– ECLIPSE registrational program in chronic hepatitis delta fully underway |
Loading...